The Malaria Consortium

Most malaria interventions wait for the disease to arrive. Bed nets create a barrier. Rapid diagnostic tests catch infections early. Artemisinin-based treatments fight the parasite once it's in your blood. All of these are reactive.

Seasonal malaria chemoprevention (SMC) is different. It gives healthy children a course of preventive antimalarial drugs before the rainy season, when malaria transmission peaks. The drugs (sulfadoxine-pyrimethamine plus amodiaquine, administered monthly for 3-4 months) prevent infection entirely during the highest-risk period. It's a vaccine-like approach without a vaccine: you take the treatment before you're sick.

The Malaria Consortium is one of the leading implementers of SMC globally, and one of GiveWell's top-rated charities. In 2023, they reached approximately 25 million children with SMC across seven countries in the Sahel and sub-Sahel regions of Africa (Malaria Consortium / SMC Alliance, 2023). Across the wider SMC Alliance, more than 50 million children were covered for the first time that year. The evidence base is strong, the cost is low, and the scale is genuinely impressive.

The evidence

The WHO recommended SMC in 2012 based on a systematic review of 12 randomised controlled trials. The Cochrane review (Meremikwu et al., 2012, updated 2022) found that SMC reduces clinical malaria episodes by approximately 75% during the transmission season. That's a larger effect size than almost any other malaria intervention, including bed nets (which reduce all-cause child mortality by roughly 17%).

The key qualification: SMC works specifically in areas with highly seasonal malaria transmission, where 60%+ of cases occur during a defined rainy season of 3-4 months. This is the Sahel pattern: Burkina Faso, Mali, Niger, Nigeria, Chad, Guinea, Senegal, The Gambia, and parts of neighbouring countries. In areas with year-round transmission (much of central Africa), SMC's seasonal approach doesn't apply.

Within its geographic sweet spot, the evidence is about as strong as it gets in public health. The ACCESS-SMC project (2015-2017), the largest implementation trial, treated 7.5 million children across seven countries and confirmed the trial results held at scale: 75% reduction in malaria episodes, significant reduction in severe malaria, and measurable reduction in all-cause mortality.

The cost-effectiveness case

GiveWell estimates the cost of protecting one child through a full seasonal course of SMC (typically four monthly cycles) at roughly $7, with the cost of delivering a single monthly cycle around $1.50. In terms of cost per death averted, GiveWell estimates roughly $2,000 to $7,000 depending on location (as of late 2023), making SMC comparable to or more cost-effective than bed net distribution through the Against Malaria Foundation.

Most of the cost is delivery rather than drugs. The medicines themselves are cheap. The bulk of the spend goes on getting them to children in remote rural areas during the rainy season, when roads become impassable and logistics become genuinely difficult, plus supervision and monitoring.

The programme's cost-effectiveness has improved over time as the Malaria Consortium has scaled. Unit costs dropped roughly 25% between 2018 and 2023, primarily through better supply chain management and training of community health workers who deliver the drugs door-to-door.

What makes it work

Four implementation features worth understanding.

Community health workers. SMC is delivered door-to-door by trained community health workers (CHWs) who visit households during each monthly cycle. This model reaches children who would never visit a health clinic, including the most remote and poorest communities. The Malaria Consortium trains and equips tens of thousands of CHWs each year to carry out SMC delivery.

Directly observed treatment. The first dose of each monthly cycle is administered by the CHW in the household and observed. The remaining two days of treatment are left with the caregiver with instructions. Adherence to the full three-day course is high for a drug regimen of this kind, which matters for maintaining efficacy, and the Malaria Consortium monitors it through household follow-up.

Integration with national health systems. Unlike some NGO-delivered programmes that create parallel structures, SMC is implemented through national malaria control programmes. The Malaria Consortium provides technical assistance, training, and drug procurement, but delivery runs through government health systems. This means the programme builds local capacity rather than replacing it.

Monitoring and pharmacovigilance. The Malaria Consortium tracks adverse events systematically. Serious adverse events from SMC drugs are rare, and the drugs have long featured on the WHO Essential Medicines List. The monitoring data is shared with national regulatory authorities and published in annual reports.

The limitations, honestly

Geographic constraint. SMC only works in the seasonal malaria belt, where hundreds of millions of children are at risk. It's a lot, but it's not the entire malaria burden. Countries like the DRC and Mozambique, which carry some of the highest malaria burdens globally, have year-round transmission and can't use SMC.

Drug resistance risk. Any mass drug administration raises concerns about antimicrobial resistance. The WHO monitors resistance to sulfadoxine-pyrimethamine and amodiaquine across the Sahel. As of 2024, resistance levels remain below thresholds that would compromise efficacy, but the Malaria Consortium's own strategic plan acknowledges this as the primary long-term risk to the programme.

Not a permanent solution. SMC treats the symptom (seasonal malaria episodes) rather than the cause (mosquito-borne transmission). It needs to be repeated every year. The long-term solution is either malaria elimination (through a combination of vector control, treatment, and eventually vaccines) or sustained annual SMC delivery indefinitely. Neither is cheap.

Coverage gaps. Despite reaching tens of millions of children, a meaningful share of eligible children in target countries still go unreached each year, primarily due to insecurity in parts of the Sahel (northern Nigeria, Mali, Burkina Faso) and logistical constraints in the most remote areas.

How it complements other interventions

SMC doesn't replace bed nets or treatment. It stacks with them. The ACCESS-SMC data showed that children who both slept under nets and received SMC had roughly 85% fewer malaria episodes than children with neither intervention. The combination is more effective than either alone, and the costs are additive, not duplicative.

The R21/Matrix-M malaria vaccine (approved by WHO in 2023) adds another layer. The vaccine provides roughly 75% protection in the first year but efficacy wanes over subsequent years. The current WHO recommendation is for the vaccine AND continued SMC where seasonal transmission patterns exist. Over the next decade, the combination of vaccine, nets, and SMC may drive malaria mortality toward near-elimination levels in the Sahel.

For your giving

The Malaria Consortium is one of the strongest options for donors who want high-confidence, high-impact giving. The evidence is robust, the cost-effectiveness is in GiveWell's top tier, and the organisation has demonstrated the ability to scale while maintaining quality.

You can donate directly via the Malaria Consortium's website or through GiveWell's recommended charities page. GiveWell's "Maximum Impact Fund" also allocates significantly to SMC when the Malaria Consortium has room for more funding.

One sentence

The Malaria Consortium prevents malaria before it starts, reaching tens of millions of children a year with proven drugs at roughly $7 per child for a full seasonal course, and it's one of the most cost-effective ways to save a life that currently exists.

Sources

1. Malaria Consortium – Seasonal Malaria Chemoprevention | GiveWell (accessed June 2026)
2. Seasonal Malaria Chemoprevention | GiveWell (accessed June 2026)
3. 53 million children living in 18 countries covered with Seasonal Malaria Chemoprevention in 2023 (SMC Alliance) (accessed June 2026)
4. Insecticide-treated nets for preventing malaria (Cochrane review) (accessed June 2026)
5. World malaria report 2024 (WHO) (accessed June 2026)
6. Malaria Consortium: Seasonal Malaria Chemoprevention Programme (Giving What We Can) (accessed June 2026)

Keep reading

Get the next one in your inbox. Every Tuesday. Free.